参麦注射液应用于宫颈癌同期放化疗中的疗效观察  

Efficacy of Shenmai Injection in Radiotherapy and Chemotherapy of Cervical Cancer

作　　者：高山[1] 王会霞[1] 岳成山 王佩[1] 余昌 

机构地区：[1]陕西省汉中市中心医院,723000

出　　处：《实用癌症杂志》2017年第5期805-807,813,共4页The Practical Journal of Cancer

摘　　要：目的探讨参麦注射液应用于宫颈癌同期放化疗中的疗效。方法选取宫颈癌患者200例,按照数字表法随机分组。对照组给予同期化疗+放疗,试验组给予同期化疗+参麦注射液+放疗。对比分析2组患者治疗效果及患者的5年后无病生存率及放射性肠炎发生率情况。结果试验组患者的总有效率(95.00%)明显高于对照组患者的(58.00%),差异有统计学意义(P<0.05)。试验组患者5年后无病生存率(75.00%)明显高于对照组患者(49.00%),且试验组患者的放射性肠炎发生率(4.00%)明显低于对照组患者的(31.00%),差异有统计学意义(P<0.05)。结论参麦注射液应用于宫颈癌同期放化疗中的疗效显著,可以提高生存率,避免放射性肠炎的发生,安全可靠。Objective To analyze the efficacy of Shenmai injection in simultaneous radiotherapy and chemotherapy of cervical cancer. Methods 200 cases of eervieal cancer were divided into 2 groups, according to randomized digital table, each with 100 cases. The control group received concurrent chemotherapy and radiation therapy, and the experimental group were given chemotherapy ＋ Shenmai injection ＋ radiation therapy. The disease-free survival rate and the incidence of radiation enteritis after 5 years of treatment were observed and compared. Results The overall response rate of the experimental group （ 95.00% ） was obviously higher than that of the control group （ 58.00% ）, the difference was statistically significant （ P 〈 0.05 ）. The disease- free survival rate of the experimental group （75.00%） was significantly higher than that of the control group （49.00%）, while the incidence of radiation enteritis （4.00%） was significantly lower than that of the control group （31.00%） ,the difference was statistically significant （ P 〈 0. 05 ）. Conclusion Shenmai injection in the concurrent radiotherapy and chemotherapy of cervical cancer patients is effective, improves clinical symptoms, increases the survival rate, avoids the occurrence of radiation enteritis, is safe and reliable.

关 键 词：宫颈癌 参麦注射液 同期放疗 化疗 

分 类 号：R737.33[医药卫生—肿瘤]